calendar
6 catalysts · 18,987 approval · 5,000 device 510k · 4,728 grant · 3,921 phase readout · 2,141 8k filing · 2,000 device pma
next 91 dayslessmore
MonWedFri
6 catalysts · 18,987 approval · 5,000 device 510k · 4,728 grant · 3,921 phase readout · 2,141 8k filing · 2,000 device pma
Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome (Preleukemia)
Therapy area: Oncology. Indication: Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma
Therapy area: Gastrointestinal. Indication: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)
Therapy area: Cardiovascular, Gastrointestinal. Indication: Endothelial Dysfunction, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)
Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Prostate Cancer, Prostate Cancer
This page contains notices of advisory committee meetings. Refer to the individual meeting link below for more information on the anticipated format of each meeting. For previous years' advisory committee calendars, see the FDA Archive.